Copyright © Inderes 2011 - present. All rights reserved.

OssDsign

11,26 SEK

+5,23 %

Mindre end 1K følgere

OSSD

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+5,23 %
+0,90 %
-29,27 %
-19,57 %
+14,20 %
+20,43 %
+127,70 %
+3,13 %
-35,20 %

OssDsign is a developer and supplier of orthobiological products. The company develops and markets products that support the body's own healing ability, such as OssDsign Catalyst, which is a nanosynthetic bone graft for dual bone formation pathways through fusion mass. The company offers its products around the global market. OssDsign was founded in 2011 and is headquartered in Uppsala.

Læs mere
Markedsværdi
1,25 mia. SEK
Aktieomsætning
4,65 mio. SEK
Omsætning
133,94 mio.
EBIT %
-36,9 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
10.2
2026

Årsrapport '25

ViserAlle indholdstyper
Eksterne analyser

OssDsign: Case intact despite slightly slower momentum - ABG

* Major beat on EBIT, but lower sales* Estimates up on adj. EBIT for '25e-'26e (lower loss), yet down for '27e* Fair value range down to SEK 10-17 (11-18)Continued operational leverage despite sales missOssDsign delivered a mixed set of numbers in Q3...

OssDsign

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Eksterne analyser

OssDsign: Strong cost control in Q3 - ABG

* 35% organic sales growth in Q3 (ABGSCe +38%)Adj. EBIT +37% vs ABGSCe* No change in outlookQ3 resultsOssDsign reported a mixed set of numbers in Q3 with lower sales but strong cost control and operational leverage. Q3 sales came in at SEK 44.2m (-4%...

OssDsign
Eksterne analyser

OssDsign: Encouraging core despite near-term headwinds - ABG

* 38% y-o-y organic sales growth in Q3'25e* EBIT forecasts cut by 4.0-6.1% for '25e-'27e* Q3'25 results due 4 NovemberQ3'25 expectationsWe expect OssDsign to report Q3 sales of SEK 46.2m and EBIT of SEK -8.5m, implying continued solid sales momentum ...

OssDsign
Eksterne analyser

Ossdsign: Another solid step forward - ABG

- Strong growth and gross margin continued in Q2'25 -EBIT revised up by 11% for '25e and 4% for '26e-'27e - Fair value range narrowed to SEK 12-18 (10-18) Another strong set of numbers In Q2, OssDsign delivered an adj. EBIT beat of 28% vs. ABGSCe, driven...

OssDsign
Eksterne analyser

Ossdsign: Impressive sales growth - ABG

- Sales beat and higher gross margin - Adj. EBIT +28% vs ABGSCe - Estimates likely to be revised up 8-12% on EBIT '25e Q2 results OssDsign reported a strong set of numbers in Q2 with sales of SEK 46.5m (+11% vs ABGSCe SEK 41.8m, no consensus) and adj...

OssDsign
Eksterne analyser

Ossdsign: Cash injection supports growth - ABG

50% y-o-y organic sales growth in Q2'25e EBIT forecasts raised by 1.0-55.7% for '25e-'27e Q2'25 results due 19 August Q2'25 expectations We expect the positive sales momentum to have continued for OssDsign in Q2, driven by continued improved market access...

OssDsign
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.